With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials:
SENS-111 and SENS-401

20190603 pipeline

 

Latest news

  • 07 Nov 2019

    Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover. Read

  • 31 Oct 2019

    Sensorion reports its 2019 first half results - Signature of a framework agreement with Institut Pasteur in gene therapy - Financial position strengthened with the issuance of a €20m mandatory convertible bond. Read

Patient center

Corporate presentation